$NHHS
NorthStar Healthcare Income, Inc.

2022 Q1 Form 10-Q Financial Statement

#000150370722000017 Filed on May 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $43.33M $57.33M
YoY Change -24.42% -21.34%
Cost Of Revenue $32.89M $45.62M
YoY Change -27.89% -0.18%
Gross Profit $10.44M $11.72M
YoY Change -10.91% -56.91%
Gross Profit Margin 24.09% 20.43%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $9.923M $15.39M
YoY Change -35.51% -6.68%
% of Gross Profit 95.07% 131.33%
Operating Expenses
YoY Change
Operating Profit
YoY Change
Interest Expense $10.31M $16.03M
YoY Change -35.67% -3.92%
% of Operating Profit
Other Income/Expense, Net $72.00K $7.360M
YoY Change -99.02%
Pretax Income -$15.47M -$9.250M
YoY Change 67.22% -19.84%
Income Tax $15.00K $15.00K
% Of Pretax Income
Net Earnings -$12.98M -$10.16M
YoY Change 27.83% -19.06%
Net Earnings / Revenue -29.96% -17.71%
Basic Earnings Per Share -$0.07 -$0.05
Diluted Earnings Per Share -$0.07 -$0.05
COMMON SHARES
Basic Shares Outstanding 193.4M shares 190.6M shares
Diluted Shares Outstanding 193.4M shares 190.6M shares

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $191.2M $90.97M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill $21.39M
YoY Change 0.0%
Intangibles $2.506M
YoY Change
Long-Term Investments $207.4M $221.9M
YoY Change -6.54% -16.35%
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets $1.391B $1.882B
YoY Change -26.11% -11.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities
Total Liabilities $954.8M $1.478B
YoY Change -35.42% 0.86%
SHAREHOLDERS EQUITY
Retained Earnings -$1.291B -$1.313B
YoY Change -1.72% 24.62%
Common Stock $1.725B $1.714B
YoY Change 0.64% 0.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $433.7M $401.2M
YoY Change
Total Liabilities & Shareholders Equity $1.391B $1.882B
YoY Change -26.11% -11.22%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$12.98M -$10.16M
YoY Change 27.83% -19.06%
Depreciation, Depletion And Amortization $9.923M $15.39M
YoY Change -35.51% -6.68%
Cash From Operating Activities -$10.84M -$6.660M
YoY Change 62.81% -374.19%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities $4.716M $44.68M
YoY Change -89.44% -3631.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$4.297M -$20.34M
YoY Change -78.88% 151.58%
NET CHANGE
Cash From Operating Activities -$10.84M -$6.660M
Cash From Investing Activities $4.716M $44.68M
Cash From Financing Activities -$4.297M -$20.34M
Net Change In Cash -$10.42M $17.67M
YoY Change -158.99% -355.3%
FREE CASH FLOW
Cash From Operating Activities -$10.84M -$6.660M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001503707
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12981000 USD
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#RealEstateInvestmentPropertyNet
CY2022Q1 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherLiabilities
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Entity File Number
EntityFileNumber
000-55190
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
NORTHSTAR HEALTHCARE INCOME, INC.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
MD
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3663988
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
4350 East West Highway
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1050
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
CY2022Q1 dei City Area Code
CityAreaCode
240
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
479-7115
CY2022Q1 dei Security12b Title
Security12bTitle
Common stock, par value $0.01 per share
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
194037776 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191228000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200473000 USD
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
9286000 USD
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
10465000 USD
CY2022Q1 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
965489000 USD
CY2021Q4 us-gaap Real Estate Investment Property Net
RealEstateInvestmentPropertyNet
972599000 USD
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
207435000 USD
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
212309000 USD
CY2022Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
2106000 USD
CY2021Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
3666000 USD
CY2022Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2506000 USD
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2590000 USD
CY2022Q1 us-gaap Other Assets
OtherAssets
12749000 USD
CY2021Q4 us-gaap Other Assets
OtherAssets
10771000 USD
CY2022Q1 us-gaap Assets
Assets
1390799000 USD
CY2021Q4 us-gaap Assets
Assets
1412873000 USD
CY2022Q1 us-gaap Notes Payable
NotesPayable
926598000 USD
CY2021Q4 us-gaap Notes Payable
NotesPayable
929811000 USD
CY2022Q1 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
4141000 USD
CY2021Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
7338000 USD
CY2022Q1 us-gaap Advance Payments By Borrowers For Taxes And Insurance
AdvancePaymentsByBorrowersForTaxesAndInsurance
1466000 USD
CY2021Q4 us-gaap Advance Payments By Borrowers For Taxes And Insurance
AdvancePaymentsByBorrowersForTaxesAndInsurance
1171000 USD
CY2022Q1 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
19317000 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
24671000 USD
CY2022Q1 us-gaap Other Liabilities
OtherLiabilities
3253000 USD
CY2021Q4 us-gaap Other Liabilities
OtherLiabilities
3064000 USD
CY2022Q1 us-gaap Liabilities
Liabilities
954775000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
966055000 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
193818780 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
193818780 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
193120940 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
193120940 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
1937000 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1930000 USD
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1723456000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1720719000 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1290624000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1277688000 USD
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1054000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-486000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
433715000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
444475000 USD
CY2022Q1 us-gaap Minority Interest
MinorityInterest
2309000 USD
CY2021Q4 us-gaap Minority Interest
MinorityInterest
2343000 USD
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
436024000 USD
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
446818000 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1390799000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1412873000 USD
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
10755000 USD
CY2021Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
28282000 USD
CY2022Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
32559000 USD
CY2021Q1 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
29051000 USD
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32894000 USD
CY2022Q1 us-gaap Other Operating Income
OtherOperatingIncome
18000 USD
CY2021Q1 us-gaap Other Operating Income
OtherOperatingIncome
1000 USD
CY2022Q1 us-gaap Revenues
Revenues
43332000 USD
CY2021Q1 us-gaap Revenues
Revenues
57334000 USD
CY2022Q1 us-gaap Interest Income Debt Securities Operating
InterestIncomeDebtSecuritiesOperating
0 USD
CY2021Q1 us-gaap Interest Income Debt Securities Operating
InterestIncomeDebtSecuritiesOperating
2213000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
45618000 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
10309000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
16025000 USD
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0 USD
CY2021Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
54000 USD
CY2022Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
2647000 USD
CY2021Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
2769000 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3686000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3033000 USD
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
83672000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9923000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15387000 USD
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
786000 USD
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
59459000 USD
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7360000 USD
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
587000 USD
CY2021Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
7515000 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-15468000 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9250000 USD
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2502000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-890000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 USD
CY2022Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4171000 USD
CY2021Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
45722000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12981000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-10155000 USD
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-45000 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
308000 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12936000 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10463000 USD
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
193368486 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
193368486 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
190630723 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
190630723 shares
CY2022Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2021Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-13549000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-10629000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15387000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-10155000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-568000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-474000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-568000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-474000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-45000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
308000 USD
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13504000 USD
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10937000 USD
CY2020Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
412062000 USD
CY2021Q1 nshi Stock Redeemedor Called During Period Value Paymentof Advisor Asset Management Fees
StockRedeemedorCalledDuringPeriodValuePaymentofAdvisorAssetManagementFees
2500000 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
46000 USD
CY2021Q1 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
240000 USD
CY2021Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
350000 USD
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
58000 USD
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
653000 USD
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-474000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-10155000 USD
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
403869000 USD
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
446818000 USD
CY2022Q1 nshi Stock Redeemedor Called During Period Value Paymentof Advisor Asset Management Fees
StockRedeemedorCalledDuringPeriodValuePaymentofAdvisorAssetManagementFees
2729000 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15000 USD
CY2022Q1 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
64000 USD
CY2022Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
53000 USD
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-568000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12981000 USD
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
436024000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12981000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-10155000 USD
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2502000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-890000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9923000 USD
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
786000 USD
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
804000 USD
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
784000 USD
CY2022Q1 us-gaap Straight Line Rent
StraightLineRent
0 USD
CY2021Q1 us-gaap Straight Line Rent
StraightLineRent
-7639000 USD
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
0 USD
CY2021Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
112000 USD
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
154000 USD
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
147000 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
48000 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
46000 USD
CY2022Q1 nshi Paid In Kind Interest Added To Real Estate Debt Investment Loan Principal
PaidInKindInterestAddedToRealEstateDebtInvestmentLoanPrincipal
0 USD
CY2021Q1 nshi Paid In Kind Interest Added To Real Estate Debt Investment Loan Principal
PaidInKindInterestAddedToRealEstateDebtInvestmentLoanPrincipal
105000 USD
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
587000 USD
CY2021Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
7515000 USD
CY2022Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2647000 USD
CY2021Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2500000 USD
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-1502000 USD
CY2021Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
833000 USD
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1665000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
7686000 USD
CY2022Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-3115000 USD
CY2021Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-4506000 USD
CY2022Q1 nshi Increase Decreasein Escrow Payable
IncreaseDecreaseinEscrowPayable
295000 USD
CY2021Q1 nshi Increase Decreasein Escrow Payable
IncreaseDecreaseinEscrowPayable
535000 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5751000 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-5336000 USD
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
327000 USD
CY2021Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
221000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10843000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6660000 USD
CY2022Q1 nshi Paymentsto Improve Real Estate
PaymentstoImproveRealEstate
2337000 USD
CY2021Q1 nshi Paymentsto Improve Real Estate
PaymentstoImproveRealEstate
2416000 USD
CY2022Q1 nshi Proceeds From Sale Of Real Estate Investing
ProceedsFromSaleOfRealEstateInvesting
0 USD
CY2021Q1 nshi Proceeds From Sale Of Real Estate Investing
ProceedsFromSaleOfRealEstateInvesting
21258000 USD
CY2022Q1 us-gaap Proceeds From Sale And Collection Of Mortgage Notes Receivable
ProceedsFromSaleAndCollectionOfMortgageNotesReceivable
0 USD
CY2021Q1 us-gaap Proceeds From Sale And Collection Of Mortgage Notes Receivable
ProceedsFromSaleAndCollectionOfMortgageNotesReceivable
24878000 USD
CY2022Q1 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0 USD
CY2021Q1 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
250000 USD
CY2022Q1 us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
7053000 USD
CY2021Q1 us-gaap Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital
ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
859000 USD
CY2022Q1 nshi Proceeds From Real Estate Debt Investment Modification Fee
ProceedsFromRealEstateDebtInvestmentModificationFee
0 USD
CY2021Q1 nshi Proceeds From Real Estate Debt Investment Modification Fee
ProceedsFromRealEstateDebtInvestmentModificationFee
346000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4716000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
44675000 USD
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
CY2021Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
26000000 USD
CY2022Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
CY2021Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
362000 USD
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
137000 USD
CY2021Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
149000 USD
CY2022Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
64000 USD
CY2021Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
240000 USD
CY2022Q1 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
53000 USD
CY2021Q1 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
350000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4297000 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-20343000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10424000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
17672000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
210938000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93570000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
200514000 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111242000 USD
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
9121000 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
16847000 USD
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
364000 USD
CY2021Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
575000 USD
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
Business and Organization<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NorthStar Healthcare Income, Inc., together with its consolidated subsidiaries (the “Company”), manages a diversified portfolio of investments in healthcare real estate, owned directly or through joint ventures, with a focus on the mid-acuity seniors housing sector, which the Company defines as assisted living (“ALF”), memory care (“MCF”), skilled nursing (“SNF”), independent living facilities (“ILF”) and continuing care retirement communities (“CCRC”), which have independent living, assisted living, skilled nursing and memory care available on one campus. Primarily through joint ventures, the Company is also invested in other healthcare property types, including medical office buildings (“MOB”), hospitals, rehabilitation facilities and ancillary healthcare services businesses. The Company’s investments are predominantly in the United States, but through its joint ventures also has international investments in the United Kingdom. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was formed in October 2010 as a Maryland corporation and commenced operations in February 2013. The Company elected to be taxed as a real estate investment trust (“REIT”) under the Internal Revenue Code of 1986, as amended (the “Internal Revenue Code”), commencing with the taxable year ended December 31, 2013. The Company has conducted its operations, and intends to do so in the future, so as to continue to qualify as a REIT for U.S. federal income tax purposes.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of the Company’s business is conducted through NorthStar Healthcare Income Operating Partnership, LP (the “Operating Partnership”). The Company is the sole general partner of the Operating Partnership. The limited partners of the Operating Partnership are NorthStar Healthcare Income Advisor, LLC (the “Prior Advisor”) and NorthStar Healthcare Income OP Holdings, LLC (the “Special Unit Holder”), each an affiliate of the Company’s sponsor. The Prior Advisor invested $1,000 in the Operating Partnership in exchange for common units and the Special Unit Holder invested $1,000 in the Operating Partnership and was issued a separate class of limited partnership units (the “Special Units”), which are collectively recorded as non-controlling interests on the accompanying consolidated balance sheets as of March 31, 2022 and December 31, 2021. As the Company issued shares, it contributed substantially all of the proceeds from its continuous, public offerings to the Operating Partnership as a capital contribution. As of March 31, 2022, the Company’s limited partnership interest in the Operating Partnership was 99.99%.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s charter authorizes the issuance of up to 400.0 million shares of common stock with a par value of $0.01 per share and up to 50.0 million shares of preferred stock with a par value of $0.01 per share. The board of directors of the Company is authorized to amend its charter, without the approval of the stockholders, to increase the aggregate number of authorized shares of capital stock or the number of shares of any class or series that the Company has authority to issue.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is externally managed and has no employees. On February 28, 2022, the Company’s former Sponsor, DigitalBridge Group, Inc. (NYSE: DBRG) (the “Former Sponsor”), completed the previously announced disposition of its wellness infrastructure platform (the “Sponsor Transaction”). Following completion of the Sponsor Transaction, NRF Holdco, LLC (“NRF” or the “New Sponsor”) (and together with the Former Sponsor, the Sponsor as the context requires), owns the Company’s advisor, CNI NSHC Advisors, LLC (the “Advisor”), as well as its own diversified portfolio of medical office buildings, senior housing facilities, skilled nursing facilities and specialty hospitals. NRF is wholly owned by CWP Bidco LP, an entity affiliated with Highgate, a privately held real estate investment and hospitality management company, and Aurora Health Network LLC, a privately held healthcare-focused investment firm. In addition, upon completion of the Sponsor Transaction, employees of the Former Sponsor focused on the wellness infrastructure platform became employees of the New Sponsor. The Advisor, now a subsidiary of the New Sponsor, will continue to manage the Company’s day-to-day operations pursuant to an advisory agreement.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through March 31, 2022, the Company raised $2.0 billion in total gross proceeds from the sale of shares of common stock in its continuous, public offerings (the “Offering”), including $232.6 million pursuant to its distribution reinvestment plan (the “DRP”). </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impact of COVID-19</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The world continues to experience the broad effects of the coronavirus 2019 (“COVID-19”) pandemic. The Company's healthcare real estate business and investments have experienced declines in resident occupancy, lower labor force participation rates, which drove increased labor costs, and inflationary pressures on other operating expenses. These impacts of COVID-19 are expected to last, even as states and municipalities have eased and may further ease restrictions. </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing impact of the COVID-19 pandemic on the Company’s operational and financial performance will depend on a variety of factors, which may differ considerably across regions and fluctuate over time. An extended recovery period increases the risk of a prolonged negative impact on the Company’s financial condition and results of operations. While the Company has </span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ability to meet its near term liquidity needs, general market concerns over credit and liquidity continue, and the effects of COVID-19 may also lead to heightened risk of litigation, with an ensuing increase in litigation and related costs.</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, the progression of the global economic recovery from the broad effects of COVID-19 remains difficult for the Company to assess and estimate the future impact of COVID-19 on the Company's results of operations. Accordingly, any estimates of the effects of COVID-19 as reflected or discussed in these financial statements are based upon the Company's best estimates using information known to the Company as of the date of this Quarterly Report on Form 10-Q, and such estimates may change, the effects of which could be material. The Company will continue to monitor the progression of the economic recovery from COVID-19 and reassess its effects on the Company’s results of operations and recoverability of value across its assets as conditions change.</span></div>
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2000000000 USD
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
207400000 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that could affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates and assumptions. Any estimates of the effects of COVID-19 as reflected and/or discussed in these financial statements are based upon the Company's best estimates using information known to the Company as of the date of this Quarterly Report on Form 10-Q. Such estimates may change and the impact of which could be material.</span></div>
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
191228000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
200473000 USD
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
9286000 USD
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
10465000 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
200514000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
210938000 USD
CY2022Q1 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
2500000 USD
CY2022Q1 nshi Finance Lease Payments
FinanceLeasePayments
100000 USD
CY2021Q1 nshi Finance Lease Payments
FinanceLeasePayments
200000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
334000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
93000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
60000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
29000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
24000 USD
CY2022Q1 nshi Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
28000 USD
CY2022Q1 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
568000 USD
CY2022Q1 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
37000 USD
CY2022Q1 us-gaap Finance Lease Liability
FinanceLeaseLiability
531000 USD
CY2022Q1 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.064
CY2022Q1 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2022Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
117643000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
117559000 USD
CY2022Q1 nshi Number Of Triple Net Lease Portfolios
NumberOfTripleNetLeasePortfolios
4 portfolio
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2506000 USD
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2590000 USD
CY2022Q1 nshi Amortizationof Deferred Costsand Intangible Assets
AmortizationofDeferredCostsandIntangibleAssets
100000 USD
CY2021Q1 nshi Amortizationof Deferred Costsand Intangible Assets
AmortizationofDeferredCostsandIntangibleAssets
500000 USD
CY2022Q1 nshi Deferred Costsand Finite Lived Intangible Assets Amortization Expense Remainderof Fiscal Year
DeferredCostsandFiniteLivedIntangibleAssetsAmortizationExpenseRemainderofFiscalYear
253000 USD
CY2022Q1 nshi Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year One
DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearOne
337000 USD
CY2022Q1 nshi Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year Two
DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
337000 USD
CY2022Q1 nshi Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year Three
DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearThree
337000 USD
CY2022Q1 nshi Deferred Costs And Finite Lived Intangible Assets Amortization Expense Year Four
DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseYearFour
337000 USD
CY2022Q1 nshi Deferred Costs And Finite Lived Intangible Assets Amortization Expense After Year Four
DeferredCostsAndFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
905000 USD
CY2022Q1 nshi Deferred Costsand Finite Lived Intangible Assets Net
DeferredCostsandFiniteLivedIntangibleAssetsNet
2506000 USD
CY2022Q1 nshi Ownership Interestin Condominiums
OwnershipInterestinCondominiums
2030000 USD
CY2021Q4 nshi Ownership Interestin Condominiums
OwnershipInterestinCondominiums
2030000 USD
CY2022Q1 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
6524000 USD
CY2021Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
4948000 USD
CY2022Q1 us-gaap Incentive To Lessee
IncentiveToLessee
3343000 USD
CY2021Q4 us-gaap Incentive To Lessee
IncentiveToLessee
3209000 USD
CY2022Q1 nshi Utility Deposit Assets
UtilityDepositAssets
219000 USD
CY2021Q4 nshi Utility Deposit Assets
UtilityDepositAssets
142000 USD
CY2022Q1 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
633000 USD
CY2021Q4 us-gaap Other Assets Miscellaneous
OtherAssetsMiscellaneous
442000 USD
CY2022Q1 us-gaap Other Assets
OtherAssets
12749000 USD
CY2021Q4 us-gaap Other Assets
OtherAssets
10771000 USD
CY2022Q1 nshi Lease Terms Days Notice Required For Termination
LeaseTermsDaysNoticeRequiredForTermination
30 D
CY2022Q1 nshi Lease Terms Days Notice Required For Termination
LeaseTermsDaysNoticeRequiredForTermination
30 D
CY2022Q1 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
1600000 USD
CY2021Q1 us-gaap Operating Lease Variable Lease Income
OperatingLeaseVariableLeaseIncome
3300000 USD
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
800000 USD
CY2022Q1 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0 USD
CY2021Q1 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0 USD
CY2022Q1 nshi Acquisition Feeand Expense Cap
AcquisitionFeeandExpenseCap
0.060
CY2022Q1 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
13600000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 USD
CY2022Q1 us-gaap Land
Land
121518000 USD
CY2021Q4 us-gaap Land
Land
121518000 USD
CY2022Q1 us-gaap Land Improvements
LandImprovements
17826000 USD
CY2021Q4 us-gaap Land Improvements
LandImprovements
17798000 USD
CY2022Q1 us-gaap Investment Building And Building Improvements
InvestmentBuildingAndBuildingImprovements
967934000 USD
CY2021Q4 us-gaap Investment Building And Building Improvements
InvestmentBuildingAndBuildingImprovements
965630000 USD
CY2022Q1 us-gaap Tenant Improvements
TenantImprovements
189000 USD
CY2021Q4 us-gaap Tenant Improvements
TenantImprovements
0 USD
CY2022Q1 us-gaap Construction In Progress Gross
ConstructionInProgressGross
7240000 USD
CY2021Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
8141000 USD
CY2022Q1 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
85922000 USD
CY2021Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
84813000 USD
CY2022Q1 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
1200629000 USD
CY2021Q4 us-gaap Real Estate Investment Property At Cost
RealEstateInvestmentPropertyAtCost
1197900000 USD
CY2022Q1 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
235140000 USD
CY2021Q4 us-gaap Real Estate Investment Property Accumulated Depreciation
RealEstateInvestmentPropertyAccumulatedDepreciation
225301000 USD
CY2022Q1 us-gaap Real Estate Investments
RealEstateInvestments
965489000 USD
CY2021Q4 us-gaap Real Estate Investments
RealEstateInvestments
972599000 USD
CY2022Q1 us-gaap Depreciation
Depreciation
9800000 USD
CY2021Q1 us-gaap Depreciation
Depreciation
14900000 USD
CY2022Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
0 USD
CY2021Q1 us-gaap Impairment Of Real Estate
ImpairmentOfRealEstate
800000 USD
CY2022Q1 us-gaap Equity Method Investments
EquityMethodInvestments
207435000 USD
CY2021Q4 us-gaap Equity Method Investments
EquityMethodInvestments
212309000 USD
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2502000 USD
CY2022Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
7053000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-890000 USD
CY2021Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
859000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
25322000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
20142000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
20865000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
670775000 USD
CY2022Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
47451000 USD
CY2022Q1 nshi Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
155038000 USD
CY2022Q1 us-gaap Long Term Debt
LongTermDebt
939593000 USD
CY2022Q1 nshi Related Party Transaction Dueto Related Parties Amount Paid
RelatedPartyTransactionDuetoRelatedPartiesAmountPaid
9130000 USD
CY2022Q1 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
4141000 USD
CY2021Q4 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
7338000 USD
CY2022Q1 nshi Related Party Transaction Dueto Related Parties Amount Incurred
RelatedPartyTransactionDuetoRelatedPartiesAmountIncurred
5933000 USD
CY2022Q1 nshi Stock Redeemedor Called During Period Shares Paymentof Advisor Asset Management Fees
StockRedeemedorCalledDuringPeriodSharesPaymentofAdvisorAssetManagementFees
700000 shares
CY2022Q1 nshi Noncashor Part Noncash Acquisition Noncash Financialor Equity Instrument Consideration Shares Issuedas Paymentfor Asset Management Fees
NoncashorPartNoncashAcquisitionNoncashFinancialorEquityInstrumentConsiderationSharesIssuedasPaymentforAssetManagementFees
2700000 USD
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47500 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
45625 USD
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
175667 USD
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
223167 USD
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
122900000 USD
CY2022Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0 shares
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-45468 USD
CY2021Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
308035 USD
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
5 segment
CY2022Q1 nshi Rentaland Resident Fee Income
RentalandResidentFeeIncome
43332000 USD
CY2022Q1 us-gaap Interest Income Operating
InterestIncomeOperating
0 USD
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
32894000 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
10309000 USD
CY2022Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
0 USD
CY2022Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
2647000 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3686000 USD
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9923000 USD
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
72000 USD
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
587000 USD
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
2502000 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 USD
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12981000 USD
CY2021Q1 nshi Rentaland Resident Fee Income
RentalandResidentFeeIncome
57334000 USD
CY2021Q1 us-gaap Interest Income Operating
InterestIncomeOperating
2213000 USD
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
45618000 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
16025000 USD
CY2021Q1 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
54000 USD
CY2021Q1 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
2769000 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3033000 USD
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15387000 USD
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
786000 USD
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7360000 USD
CY2021Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
7515000 USD
CY2021Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-890000 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15000 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-10155000 USD
CY2022Q1 us-gaap Assets
Assets
1390799000 USD
CY2021Q4 us-gaap Assets
Assets
1412873000 USD
CY2022Q1 us-gaap Number Of Real Estate Properties
NumberOfRealEstateProperties
56 property
CY2022Q1 us-gaap Number Of Units In Real Estate Property
NumberOfUnitsInRealEstateProperty
6822 unit
CY2022Q1 us-gaap Noninterest Income
NoninterestIncome
43332000 USD

Files In Submission

Name View Source Status
0001503707-22-000017-index-headers.html Edgar Link pending
0001503707-22-000017-index.html Edgar Link pending
0001503707-22-000017.txt Edgar Link pending
0001503707-22-000017-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nshi-20220331.htm Edgar Link pending
nshi-20220331.xsd Edgar Link pending
nshi-20220331_cal.xml Edgar Link unprocessable
nshi-20220331_def.xml Edgar Link unprocessable
nshi-20220331_g1.jpg Edgar Link pending
nshi-20220331_g2.jpg Edgar Link pending
nshi-20220331_htm.xml Edgar Link completed
nshi-20220331_lab.xml Edgar Link unprocessable
nshi-20220331_pre.xml Edgar Link unprocessable
nshi03312022exhibit311.htm Edgar Link pending
nshi03312022exhibit312.htm Edgar Link pending
nshi03312022exhibit321.htm Edgar Link pending
nshi03312022exhibit322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending